BioLineRx Ltd. Announces CE-Mark Registration Trial Submission for Novel Treatment for Removal of Skin Lesions
7/29/2013 9:27:53 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
JERUSALEM--(BUSINESS WIRE)--BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a pivotal, CE-Mark registration trial for BL-5010P - for the non-surgical removal of skin lesions - with the German Federal Institute for Drugs and Medical Devices (BfArM), as well as with the relevant ethics committees.
Help employers find you! Check out all the jobs and post your resume.
comments powered by